Navigation Links
British Artificial Intelligence Firm Announces Exclusive License Agreement with Janssen for Clinical Stage Drug Candidates, Facilitated by Johnson & Johnson Innovation
Date:11/8/2016

LONDON, November 8, 2016 /PRNewswire/ --

BenevolentAI, a leading British artificial intelligence ("AI") company today announced significant progress in one of its key ambitions; to improve and innovate the drug development process using AI technology and provide the best medicines to the right patients.  BenevolentAI has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica NV ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by the Johnson & Johnson Innovation Centre in London.

BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates and   their extensive related portfolio of   patents.  BenevolentAI scientists leveraged the AI technology to evaluate the potential of these small molecule compounds. The results indicate that there is strong promise to develop new medicines for hard to treat diseases.  

Under the terms of the license agreement, BenevolentAI will have the sole right to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories. This agreement will enable BenevolentAI to accelerate its development pipeline and use its unique artificial intelligence technology to explore and provide a rich source of clinical data. BenevolentAI intends to begin late stage Phase IIb clinical trials in mid 2017. Financial terms were not disclosed.

Jackie Hunter, Board Director of BenevolentAI and CEO of BenevolentAI Bio, commented:

"We are delighted to have acquired rights to these compounds under a license agreement from Janssen. The agreement adds further depth to our clinical and pre-clinical development pipeline and marks a very exciting time for the role of artificial intelligence to benefit scientific discovery and humanity. The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases. Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs."


'/>"/>
SOURCE BenevolentAI
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
2. Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Councils Education U.K. Alumni Award
3. Cannabis Science, Inc. (CBIS) In Final Negotiations To Acquire British Columbia Company That Has Submitted Marihuana For Medical Purposes License Application To Health Canada
4. Smithsonians "Bionic Man" Documentary Featuring the SynCardia Total Artificial Heart Earns British Film Award
5. News Update: After 555 Days On The SynCardia Artificial Heart, Stan Larkin Is Now At Home With His Donor Heart
6. TrueCare24 Unveils Artificial Intelligence-Driven Healthcare Platform
7. Eight of The Best Total Artificial Heart Centers Honored by SynCardia
8. Worlds Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart
9. New York Times Posts Retro Report Documentary: The Total Artificial Heart - From 1st Implant to Worlds Most Used Artificial Heart
10. Global Artificial Tears Industry
11. Insulet Announces Development Partner for the OmniPod Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
Breaking Medicine Technology:
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):